AMAG Pharmaceuticals, Inc.'s Ferumoxytol Abstract Recognized as a Presidential Poster Recipient at AMAG Pharmaceuticals, Inc. Annual Scientific Meeting

Published: Oct 14, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass., Oct. 14, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced that a poster being presented today at the 2013 American College of Gastroenterology's (ACG) annual scientific meeting was recognized as a Presidential Poster Award recipient. The abstract reported on data from a sub-group analysis of IDA patients with gastrointestinal disease from the company's IDA-301 study, a phase III, placebo-controlled clinical trial that evaluated ferumoxytol treatment in adult IDA patients who have failed or could not tolerate oral iron. The ACG Abstract Selection Committee reviewed over 2,000 abstracts in advance of this year's scientific meeting. Each year, less than 5 percent of accepted abstracts receive this distinction.

Help employers find you! Check out all the jobs and post your resume.

Back to news